Physician profile
Ajay J Kirtane
NPI 1780651497
$461,674.74
in general payments reported to CMS, 2019-2025
33 companies · $355K in 2025
The $355K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,520 · 2021: $3,838 · 2022: $13K · 2023: $44K · 2024: $31K · 2025: $355K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $263K · Consulting Fee: $79K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $13K · Travel and Lodging: $8,983 · Grant: $6,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $263,090.46 |
| Consulting Fee | $79,076.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,050.00 |
| Food and Beverage | $13,385.95 |
| Travel and Lodging | $8,982.61 |
| Grant | $6,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $361,632.59 | 2019-2025 | General - Therapies, General - Vascular Access, Clinical Trial Product |
| Medtronic, INC. | $40,322.85 | 2021-2025 | Symplicity G3, Onyx Frontier, Resolute Onyx |
| Merck Sharp & Dohme LLC | $13,297.55 | 2022-2025 | |
| Medtronic Vascular, INC. | $10,852.25 | 2019-2020 | |
| Abbott Laboratories | $9,236.87 | 2022-2025 | Optis, Absolute Pro, Cardiomems |
| Biotronik INC. | $8,755.21 | 2021-2025 | Orsiro Mission, Trapit, Recross |
| Janssen Research & Development, LLC | $3,360.00 | 2024-2025 | |
| Shockwave Medical, INC | $2,487.59 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $2,460.18 | 2023 | Aprocitentan |
| Recor Medical INC | $1,810.15 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Cardiovascular Systems INC. | $1,312.67 | 2019-2022 | |
| Cathworks, INC. | $1,083.20 | 2022-2025 | Ffrangio |
| Philips North America LLC | $1,008.05 | 2021-2024 | (P88) Igt Devices Fm |
| Edwards Lifesciences Corporation | $531.82 | 2019-2025 | Sapien 3 Ultra Resilia |
| Abiomed | $490.35 | 2019-2025 | Impella |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $470.46 | 2023-2025 | Manta, Guideliner, Turnpike |
| Novartis Pharmaceuticals Corporation | $360.90 | 2022-2025 | |
| Amgen INC. | $311.92 | 2019-2025 | Repatha |
| Neovasc Medical INC | $305.48 | 2021-2022 | |
| Acist Medical Systems, INC. | $299.22 | 2023-2024 | |
| Siemens Medical Solutions USA, INC. | $219.11 | 2019 | |
| Cordis US Corp. | $214.19 | 2025 | Selution Slr Ptca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.02 | 2021-2025 | Jardiance |
| Heartflow, INC. | $135.90 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $129.72 | 2019 | |
| Asahi Intecc USA, INC. | $111.37 | 2023-2025 | Asahi Peripheral Vascular Wires, Peripheral Vascular, Asahi Ptca Guide Wire |
| W. L. Gore & Associates, INC. | $89.29 | 2022 | |
| Angiodynamics, INC. | $86.96 | 2024 | Auryon Laser System 100-120 Vac |
| Pfizer INC. | $38.41 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $37.80 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $37.12 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $22.54 | 2025 | Attruby |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Kirtane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.